Company Overview and News
2018-09-17 seekingalpha - 3
XBiotech reported preliminary positive data from an open-label, dose escalation study of Phase 2 trial assessing its bermekimab candidate in moderate to severe atopic dermatitis (AD). On September 13, the share price climbed 28% pre-market on this apparently positive news. However, in spite of two subsequent spikes during the last two days, the share price has not yet fully recovered to its price range before the mid-September slide that wiped off ~50% of its share price between September 6 ($4.
MBRX MOR IRWD REGN AZN MPSYY INCY ARQL GLPG ARDX ACOR AZN MPSYF BIIB XBIT NVS
Investors in ArQule, Inc. (ARQL - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Jan 18, 2019 $7.50 Call had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other.
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C0Y(# @;V)J#3P\+TQI;[email protected](O5'EP92]84F5F+U=;,2 R(#%=/CYS=')E86T-"FC>8F)[email protected] M8F#R A(,4X [email protected](")[email protected]<0G,P8F1H8#(%D&1G3B/^/D/P [email protected]"T8P;D M#0IE;F1S=')E86T-96YD;V)J#7-T87)T>')[email protected]*, T*)25%3T8-"B @(" @ M(" @#0HV,2 P(&]B:@T\/"]#(#8Y+T9I;'1E
2018-08-14 seekingalpha - 1
Discussion: RedHill Biopharma (RDHL) received a Notice of Allowance for its new formulation covering RHB-104 in Crohn's disease and RHB-204 in pulmonary nontuberculous mycobacteria infections. The notice allows the patent to be valid until at least 2029. Apart from Crohn’s Disease, the company has diverse program pipeline. The program includes other indications such as H. Pylori infection, migraine, and nontuberculous mycobacteria (NTM) infections.
MBIO REDIF APOP RDHL ACER ARQL MGTX STML CLRBZ CLRBW MCUJF ABBV CLRB APOPW ALNY ABBV VNRX
2018-08-03 zacks - 1
It is a known fact that small companies are a great place to find big investment returns. This article discusses the outlook for small drug companies, which make medicines for both human and veterinary use. We have a separate industry outlook discussion for some of the largest drugmakers of the world. (Read more: Large Cap Pharma Stock Outlook: Short-Term Struggle Likely)
REDIF RDHL GLMD ARQL AERI
Good day, ladies and gentlemen, and welcome to the Second Quarter 2018 ArQule, Incorporated Earnings Conference Call. At this time, all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instructions will follow given at that time. [Operator Instructions] As a reminder, this conference is being recorded.
ArQule (ARQL - Free Report) just came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to loss of $0.10 per share a year ago. These figures are adjusted for non-recurring items.
Investors focused on the Medical space have likely heard of ArQule (ARQL - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of ARQL and the rest of the Medical group's stocks.
tv498327-424b5 - none - 3.4245855s TABLE OF CONTENTS
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to ARQL / ArQule, Inc. on message board site Silicon Investor.
|ArQule, Inc. (ARQL)||ArQule, Inc. (ARQL)||ArQule, Inc. (ARQL)||ArQule (ARQL)||ArQule (ARQL)||ArQule (ARQL)|
as of ET